[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498857":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":43,"collaborators":19,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":19,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":19,"overallStatus":68,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Beijing Friendship Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"L-DEP and PD-1 antibody","EXPERIMENTAL","PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles",[13],"Drug: L-DEP and PD-1 antibody",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg\u002Fm2 day 1; etoposide 75 mg\u002Fm2 day1; methylprednisolone 1.5mg\u002Fkg days 1 to 3, 0.25mg\u002Fkg day 4 to 14; PEG-aspargase 6000iu\u002Fm2 day2, day4; PD-1 antibody injection 200mg day 5.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Zhao Wang, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","63138303","wangzhao@ccmu.edu.cn",[30],{"facility":31,"status":19,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":19},"Beijing Friendship Hospital, Capital Medical University","Beijing","Beijing Municipality","100050","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},{"type":23,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Zhao Wang","Professor and Head of hematology","100498857","phase-3-l-dep-regimen-combined-with-pd-1-antibody-as-induction-therapy-for-epstein-barr-virus-positive-la-hlh-100498857",false,"NCT05775705","L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH","The Efficacy and Safety of L-DEP Regimen Combined With PD-1 Antibody an Induction Therapy for Epstein-Barr Virus (EBV)-Positive Lymphoma-associated Hemophagocytic Lymphohistiocytosis","Inclusion Criteria:\n\n* Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis.\n* EBV-DNA in peripheral blood \\> 1000 copies\u002Fml or EBER detected in tissue specimens.\n* Age 18\\~65，gender is not limited.\n* Estimated survival time ≥ 1 month.\n* Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index \\>250.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Heart function above grade II (NYHA).\n* Severe myocardial injury：TNT、TNI、CK-MB \\> 3 ULN.\n* Accumulated dose of doxorubicin above 400mg\u002Fm2 、epirubicin above 750mg\u002Fm2、pirarubicin above 800mg\u002Fm2 or the patients treated with anthracycline induced cardiovascular disease.\n* Pregnancy or lactating Women.\n* Allergic to pegylated liposomal doxorubicin，etoposide，or PD-1 antibody.\n* Thyroid dysfunction.\n* HIV antibody positivity.\n* Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable).\n* Participate in other clinical research at the same time.\n* The researchers considered that patients are not suitable for the study.","ALL","18 Years","65 Years",{"count":57,"type":58},25,"ESTIMATED","INTERVENTIONAL",[61],"PHASE3","The efficacy and safety of L-DEP (PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.",[64,65,66,67],"PD-1 Antibody","Hemophagocytic Lymphohistiocytosis","Epstein-Barr Virus","Lymphoma","NOT_YET_RECRUITING","2023-03-08",{"date":71,"type":72},"2023-03-20","ACTUAL",{"date":74,"type":58},"2023-08-01",{"date":76,"type":58},"2026-10-01",{"name":5,"class":6},1]